Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events
Álvaro Sierra-Salazar, Yatzil Reyna-Juárez, Beatriz Alcalá-Carmona, Rodrigo Quintana-Tenorio, Jennifer T. Balderas-Miranda, Johan Camacho-Pérez, Jiram Torres-Ruiz · 2026
Read Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events by Álvaro Sierra-Salazar, Yatzil Reyna-Juárez, Beatriz Alcalá-Carmona, Rodrigo Quintana-Tenorio, Jennifer T. Balderas-Miranda, Johan Camacho-Pérez, Jiram Torres-Ruiz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13125145.txt.
Description
Immune checkpoint inhibitors (ICIs) have transformed modern cancer therapy by restoring antitumor T-cell responses through blockade of immune tolerance pathways such as CTLA-4 and PD-1/PD-L1. However, the same immune activation that underlies their clinical efficacy can also lead to immune-related adverse events (irAEs), a broad spectrum of inflammatory and autoimmune toxicities that may affect virtually any organ system.
Catalog record
| CREATOR | Álvaro Sierra-Salazar, Yatzil Reyna-Juárez, Beatriz Alcalá-Carmona, Rodrigo Quintana-Tenorio, Jennifer T. Balderas-Miranda, Johan Camacho-Pérez, Jiram Torres-Ruiz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |